Compugen Launches Predictive Discovery Platform With 200,000 Novel Genomic Variations
15 Noviembre 2006 - 7:54AM
Business Wire
Compugen Ltd. (Nasdaq:CGEN) announced today at the 2006 Cold Spring
Harbor Meeting on Pharmacogenomics the launch of its GeneVa
structural genomic variations platform providing predicted non-SNP
(Single Nucleotide Polymorphism), medium and large-scale genetic
variations in the human genome. The important role of non-SNP,
medium and large-scale genetic variations, has recently become
increasingly apparent. SNPs are genomic locations where a single
nucleotide can differ between individuals. Due to their high
frequency in the human genome, a large number of techniques are
used today to exploit SNP information for genotyping efforts.
Recent reports show that medium and large-scale insertions and
deletions are also a substantial source of polymorphism in humans
and it is expected they will facilitate theranostic and disease
predisposition studies with a higher degree of success than current
SNP only approaches. The GeneVa platform, which was announced
today, currently incorporates a database - developed during the
past year - of approximately 200,000 novel predicted insertions,
deletions and copy-number variations in the human genome.
This�database was created by analyzing genomic, EST (Expressed
Sequence Tag), disease related and other�databases. A specialized
computational biology analysis platform was developed to handle and
integrate these disparate data sources, identify possible genomic
structural variations and predict their association with specific
disease pathways such as those associated with breast and colon
cancer, diabetes type II and Parkinson�s disease. Yossi Cohen, MD,
VP Research and Discovery said, �This is another example of how the
capabilities that have been developed over the past decade at
Compugen now allow us to quickly address important unmet clinical
needs with unique predictive platforms. In this case, we are
confident that in less than a year from project initiation we have
developed the largest structural non-SNP genomic variations
database available today. We intend to utilize the GeneVa platform,
on our own and with partners, to correlate patients� genetic
profiles with clinical data such as drug response or disease
predisposition and to identify novel biomarkers for drug
development. We are also developing an experimental protocol that
will enable such studies to be performed efficiently and cost
effectively, handling thousands of variants and hundreds of
patients at a fraction of the cost of generic techniques such as
sequencing�. About Compugen Compugen�s mission is to be the world
leader in the discovery and licensing of product candidates to the
drug and diagnostic industry. The Company�s powerful discovery
engines enable the predictive discovery of numerous potential
therapeutics and diagnostic biomarkers. This capability results
from the Company�s decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen�s product discovery efforts and its
initial discovery engines have focused mainly within the areas of
cancer, immune-related and cardiovascular diseases. The Company's
primary commercialization pathway for its therapeutic and
diagnostic product candidates is to enter into milestone and
revenue sharing out-licensing and joint development agreements with
leading companies. Compugen has established an agricultural
biotechnology affiliate � Evogene, and a small-molecule drug
discovery affiliate � Keddem Bioscience. www.cgen.com This press
release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as �may�, �expects�, �anticipates�,
�believes�, and �intends�, and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to
the development of new products; and the ability to implement
technological improvements. These and other factors are identified
and more fully explained under the heading "Risk Factors" in
Compugen's annual reports filed with the Securities and Exchange
Commission. Compugen Ltd. (Nasdaq:CGEN) announced today at the 2006
Cold Spring Harbor Meeting on Pharmacogenomics the launch of its
GeneVa structural genomic variations platform providing predicted
non-SNP (Single Nucleotide Polymorphism), medium and large-scale
genetic variations in the human genome. The important role of
non-SNP, medium and large-scale genetic variations, has recently
become increasingly apparent. SNPs are genomic locations where a
single nucleotide can differ between individuals. Due to their high
frequency in the human genome, a large number of techniques are
used today to exploit SNP information for genotyping efforts.
Recent reports show that medium and large-scale insertions and
deletions are also a substantial source of polymorphism in humans
and it is expected they will facilitate theranostic and disease
predisposition studies with a higher degree of success than current
SNP only approaches. The GeneVa platform, which was announced
today, currently incorporates a database - developed during the
past year - of approximately 200,000 novel predicted insertions,
deletions and copy-number variations in the human genome. This
database was created by analyzing genomic, EST (Expressed Sequence
Tag), disease related and other databases. A specialized
computational biology analysis platform was developed to handle and
integrate these disparate data sources, identify possible genomic
structural variations and predict their association with specific
disease pathways such as those associated with breast and colon
cancer, diabetes type II and Parkinson's disease. Yossi Cohen, MD,
VP Research and Discovery said, "This is another example of how the
capabilities that have been developed over the past decade at
Compugen now allow us to quickly address important unmet clinical
needs with unique predictive platforms. In this case, we are
confident that in less than a year from project initiation we have
developed the largest structural non-SNP genomic variations
database available today. We intend to utilize the GeneVa platform,
on our own and with partners, to correlate patients' genetic
profiles with clinical data such as drug response or disease
predisposition and to identify novel biomarkers for drug
development. We are also developing an experimental protocol that
will enable such studies to be performed efficiently and cost
effectively, handling thousands of variants and hundreds of
patients at a fraction of the cost of generic techniques such as
sequencing". About Compugen Compugen's mission is to be the world
leader in the discovery and licensing of product candidates to the
drug and diagnostic industry. The Company's powerful discovery
engines enable the predictive discovery of numerous potential
therapeutics and diagnostic biomarkers. This capability results
from the Company's decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen's product discovery efforts and its
initial discovery engines have focused mainly within the areas of
cancer, immune-related and cardiovascular diseases. The Company's
primary commercialization pathway for its therapeutic and
diagnostic product candidates is to enter into milestone and
revenue sharing out-licensing and joint development agreements with
leading companies. Compugen has established an agricultural
biotechnology affiliate - Evogene, and a small-molecule drug
discovery affiliate - Keddem Bioscience. www.cgen.com This press
release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as "may", "expects", "anticipates",
"believes", and "intends", and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to
the development of new products; and the ability to implement
technological improvements. These and other factors are identified
and more fully explained under the heading "Risk Factors" in
Compugen's annual reports filed with the Securities and Exchange
Commission.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024